Neonatal GLP1R activation limits adult adiposity by durably altering hypothalamic architecture

Area of Science:

• Metabolic research
• Neuroendocrinology
• Obesity research

Background:

• Neonatal environmental factors significantly influence adult obesity risk.
• Disruptions in gut or neurohormone signaling during development can lead to adverse metabolic outcomes.
• The role of specific signaling pathways, like glucagon-like peptide-1 receptor (GLP1R), in early life programming of metabolism requires further investigation.

Purpose of the Study:

• To investigate the long-term effects of activating the GLP1R in neonates on adult adiposity and metabolic health.
• To determine if early GLP1R signaling influences energy expenditure, body composition, and susceptibility to diet-induced obesity.
• To elucidate the hypothalamic mechanisms underlying the observed metabolic changes.

Main Methods:

• Neonatal C57BL/6 mice received daily injections of Exendin-4 (Ex-4), a GLP1R agonist, for six days post-birth.
• Comprehensive assessments included growth, body composition, serum analysis, energy expenditure, and food intake up to 42 weeks.
• Specific genetic models (Sim1Cre;Glp1rloxP/loxP mice) were used to assess the role of GLP1R in the paraventricular nucleus (PVH) of the hypothalamus.

Main Results:

• Neonatal Ex-4 treatment led to reduced adult body weight and fat mass, particularly in female mice.
• Increased energy expenditure and protection against diet-induced obesity were observed.
• Key findings included the browning of white adipose tissue, altered hypothalamic neural projections, and a critical role for PVH GLP1R signaling.

Conclusions:

• Acute neonatal GLP1R activation results in durable alterations to hypothalamic architecture.
• These changes effectively limit adult weight gain and adiposity.
• GLP1R activation in neonates represents a promising therapeutic strategy for obesity prevention.